Literature DB >> 9787957

Outcome of 22 successful pregnancies after liver transplantation.

A Wu1, B Nashan, U Messner, H H Schmidt, H H Guenther, S Niesert, R Pichmayr.   

Abstract

To evaluate course and outcome of pregnancies in liver transplanted patients and to provide a brief summary on the development of these children, 22 pregnancies and 23 children (1 month-99 months old) of 16 patients who had been liver transplanted at our institution (mean interval from transplantation to pregnancy 43.1 months) were reviewed. Standard immunosuppressive regimen during pregnancy consisted of cyclosporine A (CyA), tacrolimus (FK), azathioprine (Aza) and/or a low-dose steroid therapy. CyA and FK whole blood trough levels were monitored on a routinely basis to keep therapeutic range (CyA 80-150 ng/mL; FK 4-8 ng/mL). No patient had a graft loss and there were no lethal complications. Beside de novo hypertension (n = 3) and preeclampsia (n = 3) problems during pregnancy included one steroid-sensitive rejection at 36 wk gestation, one case of tacrolimus toxicity at 24 wk with complete reconstitution, and one case of de novo choledocholithiasis with recurrent cholangitis. Three cases of infections occurred. In total, 23 children, including one set of twins, were born. Terms of gestation (mean = 38.1 wk, +/- 2.2 SD), deliveries (spontaneous n = 13, cesarean section n = 7, forceps n = 1, vacuum extraction (VE) n = 1) and birth weights (2876 g, +/- 589.3 SD) were typical. Three pregnancies were preterm, one being a twin pregnancy. Neither congenital malformations nor unusual infections were seen in the children. Postnatal follow-up revealed appropriate physical growth to date. Psychological development seems to be adequate. Our data indicate that successful pregnancies after liver transplantation (LTX) under careful management by transplant specialists, obstetricians and perinatalogists have a good outcome. So far, neither pre- nor postnatal child development appear to be influenced by maternal immunosuppressive therapy during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787957

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

1.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 2.  Pregnancy following liver transplantation: review of outcomes and recommendations for management.

Authors:  Kuljit S Parhar; Paul S Gibson; Carla S Coffin
Journal:  Can J Gastroenterol       Date:  2012-09       Impact factor: 3.522

3.  Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years.

Authors:  Ashokkumar B Jain; J Reyes; Amadeo Marcos; G Mazariegos; Bijan Eghtesad; Paulo A Fontes; Thomas V Cacciarelli; J Wallis Marsh; Michael E de Vera; Ann Rafail; Thomas E Starzl; John J Fung
Journal:  Transplantation       Date:  2003-09-15       Impact factor: 4.939

4.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

5.  Pregnancy after liver transplant: maternal and perinatal outcomes.

Authors:  Izabela Marzec; Aleksandra Słowakiewicz; Jolanta Gozdowska; Olga Tronina; Marek Pacholczyk; Wojciech Lisik; Agata Fleming; Magdalena Durlik
Journal:  BMC Pregnancy Childbirth       Date:  2021-09-16       Impact factor: 3.007

Review 6.  Follow-Up of Offspring Born to Parents With a Solid Organ Transplantation: A Systematic Review.

Authors:  Jildau R Meinderts; Jelmer R Prins; Stefan P Berger; Margriet F C De Jong
Journal:  Transpl Int       Date:  2022-08-05       Impact factor: 3.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.